Annual CFO
-$9.45 M
-$1.85 M-24.42%
December 31, 2023
Summary
- As of February 7, 2025, ATXI annual cash flow from operations is -$9.45 million, with the most recent change of -$1.85 million (-24.42%) on December 31, 2023.
- During the last 3 years, ATXI annual CFO has fallen by -$4.84 million (-104.88%).
- ATXI annual CFO is now -479.11% below its all-time high of -$1.63 million, reached on December 31, 2016.
Performance
ATXI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$2.89 M
-$636.00 K-28.23%
September 30, 2024
Summary
- As of February 7, 2025, ATXI quarterly cash flow from operations is -$2.89 million, with the most recent change of -$636.00 thousand (-28.23%) on September 30, 2024.
- Over the past year, ATXI quarterly CFO has dropped by -$565.00 thousand (-24.31%).
- ATXI quarterly CFO is now -8397.06% below its all-time high of -$34.00 thousand, reached on March 31, 2017.
Performance
ATXI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$10.59 M
-$2.00 M-23.29%
September 30, 2024
Summary
- As of February 7, 2025, ATXI TTM cash flow from operations is -$10.59 million, with the most recent change of -$2.00 million (-23.29%) on September 30, 2024.
- Over the past year, ATXI TTM CFO has dropped by -$1.14 million (-12.01%).
- ATXI TTM CFO is now -1241.70% below its all-time high of -$789.00 thousand, reached on March 31, 2017.
Performance
ATXI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ATXI Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.4% | -24.3% | -12.0% |
| 3 y3 years | -104.9% | -140.2% | -182.3% |
| 5 y5 years | +48.1% | -68.5% | +51.6% |
ATXI Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -152.0% | at low | -421.5% | +38.1% | -182.3% | +6.3% |
| 5 y | 5-year | -152.0% | +64.0% | -439.0% | +42.2% | -183.1% | +59.7% |
| alltime | all time | -479.1% | +64.0% | -8397.1% | +79.3% | -1241.7% | +59.7% |
Avenue Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.89 M(+28.2%) | -$10.59 M(+23.3%) |
| Jun 2024 | - | -$2.25 M(-27.8%) | -$8.59 M(-21.9%) |
| Mar 2024 | - | -$3.12 M(+34.3%) | -$11.00 M(+16.4%) |
| Dec 2023 | -$9.45 M(+24.4%) | -$2.32 M(+161.4%) | -$9.45 M(-16.3%) |
| Sep 2023 | - | -$889.00 K(-80.9%) | -$11.30 M(+3.1%) |
| Jun 2023 | - | -$4.67 M(+196.6%) | -$10.96 M(+51.4%) |
| Mar 2023 | - | -$1.57 M(-62.3%) | -$7.24 M(-4.7%) |
| Dec 2022 | -$7.60 M(+102.6%) | -$4.17 M(+652.5%) | -$7.60 M(+64.1%) |
| Sep 2022 | - | -$554.00 K(-41.3%) | -$4.63 M(+0.4%) |
| Jun 2022 | - | -$943.00 K(-51.1%) | -$4.61 M(+5.5%) |
| Mar 2022 | - | -$1.93 M(+60.4%) | -$4.37 M(+16.6%) |
| Dec 2021 | -$3.75 M(-18.7%) | -$1.20 M(+124.4%) | -$3.75 M(+0.3%) |
| Sep 2021 | - | -$536.00 K(-23.9%) | -$3.74 M(-9.6%) |
| Jun 2021 | - | -$704.00 K(-46.1%) | -$4.14 M(-12.9%) |
| Mar 2021 | - | -$1.31 M(+9.6%) | -$4.75 M(+2.9%) |
| Dec 2020 | -$4.61 M | -$1.19 M(+28.0%) | -$4.61 M(-45.2%) |
| Sep 2020 | - | -$932.00 K(-29.2%) | -$8.42 M(-8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$1.32 M(+12.5%) | -$9.20 M(-57.9%) |
| Mar 2020 | - | -$1.17 M(-76.6%) | -$21.86 M(-16.7%) |
| Dec 2019 | -$26.26 M(+44.2%) | -$5.00 M(+191.5%) | -$26.26 M(+16.7%) |
| Sep 2019 | - | -$1.71 M(-87.7%) | -$22.50 M(-9.7%) |
| Jun 2019 | - | -$13.98 M(+151.1%) | -$24.92 M(+46.9%) |
| Mar 2019 | - | -$5.57 M(+349.8%) | -$16.96 M(-6.9%) |
| Dec 2018 | -$18.22 M(+167.8%) | -$1.24 M(-70.1%) | -$18.22 M(-14.3%) |
| Sep 2018 | - | -$4.14 M(-31.3%) | -$21.25 M(+11.9%) |
| Jun 2018 | - | -$6.02 M(-11.7%) | -$18.99 M(+39.8%) |
| Mar 2018 | - | -$6.82 M(+59.8%) | -$13.59 M(+99.8%) |
| Dec 2017 | -$6.80 M(+316.8%) | -$4.27 M(+127.1%) | -$6.80 M(+160.9%) |
| Sep 2017 | - | -$1.88 M(+202.6%) | -$2.61 M(+122.6%) |
| Jun 2017 | - | -$621.00 K(+1726.5%) | -$1.17 M(+48.4%) |
| Mar 2017 | - | -$34.00 K(-53.4%) | -$789.00 K(-51.7%) |
| Dec 2016 | -$1.63 M | -$73.00 K(-83.5%) | -$1.63 M(+4.7%) |
| Sep 2016 | - | -$443.00 K(+85.4%) | -$1.56 M(+39.7%) |
| Jun 2016 | - | -$239.00 K(-72.7%) | -$1.12 M(+27.3%) |
| Mar 2016 | - | -$877.00 K | -$877.00 K |
FAQ
- What is Avenue Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Avenue Therapeutics?
- What is Avenue Therapeutics annual CFO year-on-year change?
- What is Avenue Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Avenue Therapeutics?
- What is Avenue Therapeutics quarterly CFO year-on-year change?
- What is Avenue Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Avenue Therapeutics?
- What is Avenue Therapeutics TTM CFO year-on-year change?
What is Avenue Therapeutics annual cash flow from operations?
The current annual CFO of ATXI is -$9.45 M
What is the all time high annual CFO for Avenue Therapeutics?
Avenue Therapeutics all-time high annual cash flow from operations is -$1.63 M
What is Avenue Therapeutics annual CFO year-on-year change?
Over the past year, ATXI annual cash flow from operations has changed by -$1.85 M (-24.42%)
What is Avenue Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ATXI is -$2.89 M
What is the all time high quarterly CFO for Avenue Therapeutics?
Avenue Therapeutics all-time high quarterly cash flow from operations is -$34.00 K
What is Avenue Therapeutics quarterly CFO year-on-year change?
Over the past year, ATXI quarterly cash flow from operations has changed by -$565.00 K (-24.31%)
What is Avenue Therapeutics TTM cash flow from operations?
The current TTM CFO of ATXI is -$10.59 M
What is the all time high TTM CFO for Avenue Therapeutics?
Avenue Therapeutics all-time high TTM cash flow from operations is -$789.00 K
What is Avenue Therapeutics TTM CFO year-on-year change?
Over the past year, ATXI TTM cash flow from operations has changed by -$1.14 M (-12.01%)